SCHEMBL2552269

SCHEMBL2552269

O=C(O)Cc1ccc(OCc2ccccc2C(=O)O)cc1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.53
TP53 P04637 2/20 0.52
HTT P42858 1/20 0.52
FFAR1 O14842 7/20 0.51
FFAR4 Q5NUL3 4/20 0.51
AKR1B1 P15121 1/20 0.49
USP2 O75604 1/20 0.49
NR4A2 P43354 1/20 0.49
PTPRC P08575 1/20 0.49
PTPN1 P18031 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.48
ALOX5 P09917 1/20 0.48
SRD5A2 P31213 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL10567951 0.98 FOLH1 (0.52) FOLH1TP53HTTFFAR1FFAR4
SCHEMBL3995720 0.86 TSHR (0.50) TP53FFAR1FFAR4AKR1B1USP2
SCHEMBL4430140 0.86 NPC1 (0.52) FOLH1TP53HTTUSP2ALOX5
SCHEMBL1368181 0.85 TP53 (0.63) FOLH1TP53HTTNR4A2PTPRC
SCHEMBL10689361 0.85 FFAR1 (0.71) FFAR1FFAR4AKR1B1
SCHEMBL5989548 0.85 RXRA (0.59) FOLH1TP53HTTFFAR1FFAR4
SCHEMBL11618778 0.84 CFD (0.55) FOLH1TP53HTTFFAR1NR4A2
SCHEMBL13870541 0.84 FFAR1 (0.56) FOLH1TP53HTTFFAR1FFAR4
SCHEMBL28141293 0.83 AKR1B1 (0.58) HTTFFAR1FFAR4AKR1B1PTPRC
SCHEMBL11621301 0.83 FFAR1 (0.60) FFAR1FFAR4AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115385887-B Method for preparing isoxadifen by catalyzing cyclization reaction through ammonium salt ionic liquid 北京联本医药化学技术有限公司 2024-01-23 CN claimed
EP-2058294-B1 METHOD FOR PRODUCING 2-(4-METHOXYCARBONYLMETHYLPHENOXYMETHYL)BENZOIC ACID METHYL ESTER SUMITOMO CHEMICAL CO (JP) 2013-01-02 EP claimed
WO-2011128911-A2 IMPROVED PROCESS FOR LL-[(Z)-3-(DIMETHYLAMINO)PROPYIIDENEL-6-LL- DIHYDRODIBENZ[B,EL OXEPIN-2-ACETICACID MSN LABORATORIES LIMITED (IN) 2011-10-20 WO claimed
EP-2181989-A2 Process for the preparation of olopatadine Sumitomo Chemical Company, Limited (JP) 2010-05-05 EP claimed
EP-2072507-A1 TERTIARY ALKYL ESTER OF OXODIBENZOXEPIN ACETIC ACID Sumitomo Chemical Company, Limited (JP) 2009-06-24 EP claimed
EP-2058294-A1 2-(4-METHOXYCARBONYLMETHYLPHENOXYMETHYL)BENZOIC ACID METHYL ESTER AND METHOD FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2009-05-13 EP claimed
EP-2004621-A2 POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF Universität Zürich (CH) 2008-12-24 EP claimed
WO-2007110761-A2 POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF Universität Zürich (CH) 2007-10-04 WO claimed
US-20070232814-A1 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof UNIVERSITAT ZURICH (CH) 2007-10-04 US claimed
CN-115385887-B Method for preparing isoxadifen by catalyzing cyclization reaction through ammonium salt ionic liquid 北京联本医药化学技术有限公司 2024-01-23 CN disclosed
CN-115385887-B Method for preparing isoxadifen by catalyzing cyclization reaction through ammonium salt ionic liquid 北京联本医药化学技术有限公司 2024-01-23 CN disclosed
CN-113620920-A Preparation method of olopatadine hydrochloride 四川子仁制药有限公司 2021-11-09 CN disclosed
CN-102838582-B Preparation method of isoxepac HUZHOU HENGYUAN BIOCHEM TECHNOLOGY CO LTD 2014-03-26 CN disclosed
EP-2181989-B1 Process for the preparation of olopatadine SUMITOMO CHEMICAL CO (JP) 2013-05-22 EP disclosed
US-4816591-A 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives AMERICAN HOECHST CORPORATION (US) 1989-03-28 US disclosed
EP-0069810-B1 NOVEL DIBENZOXEPINS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THE USE OF DIBENZOXEPINS IN THE TREATMENT OF ALLERGIC CONDITIONS MERCK & CO. INC. (US) 1986-12-03 EP disclosed
US-4585788-A 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives AMERICAN HOECHST CORPORATION (US) 1986-04-29 US disclosed
EP-0069810-A1 Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions MERCK & CO. INC. (US) 1983-01-19 EP disclosed
US-4282365-A Dibenz[b,e]oxepin compounds MERCK & CO., INC. (US) 1981-08-04 US disclosed
US-4082850-A TOPICAL APPLICATION OF A 6,11-DIHYDROBENZ(B,E)OXEPIN-ALKANOIC ACID OR DERIVATIVES THEREOF AMERICAN HOECHST CORPORATION (US) 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232814-A1 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof HRH4, HRH1, HRH3 FOLH1 3493/4885TP53 2526/4885HTT 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.